

Datasheet for 200-301-A88S**Mesothelin Antibody****Overview**

Description:	Anti-Mesothelin (MOUSE) Monoclonal Antibody - 200-301-A88S
Item No.:	200-301-A88S
Size:	25 µL
Applications:	FC, IHC, WB
Reactivity:	Human
Host Species:	Mouse

Product Details

Background:	Mesothelin is a glycosyl-phosphatidyl-inositol–anchored glycoprotein present on the cell surface of various human solid tumors. The mesothelin (MSLN) gene encodes a 71-kDa precursor protein that is processed to a 40-kDa glycosylphosphatidyl-inositol–anchored protein that composes the mature portion and an NH ₂ -terminal 31-kDa fragment called megakaryocyte-potentiating factor that is released from the cell. Mesothelin is a tumor differentiation antigen present at low levels on a restricted set of normal adult tissues, such as mesothelium, but aberrantly over expressed in mesotheliomas, ovarian, and pancreatic cancers. The biological functions of mesothelin remain elusive. A recent study showed that mesothelin binds to MUC16/CA125, and that this interaction mediates cell adhesion, suggesting that there may be an important role for MUC16/CA125 and mesothelin in the metastatic spread of ovarian cancer.
Synonyms:	mouse anti-Mesothelin Antibody, Mesothelian, MN, MB, Pre-pro-megakaryocyte-potentiating factor, CAK1 antigen
Host Species:	Mouse
Clonality:	Monoclonal
Clone ID:	MN-1
Format:	IgG2a

Target Details

Gene Name:	MSLN
Reactivity:	Human

Immunogen Type:	Recombinant Protein
Immunogen:	This antibody was produced in mesothelin-deficient mice by immunizations with plasmid cDNA encoding human MSLN full length protein followed by a single boost of a recombinant human mesothelin-Fc fusion protein.
Purity/Specificity:	This antibody is directed against human mesothelin protein. This product was purified from tissue culture supernatant fluid by Protein A chromatography. Cross reactivity with homologues from other sources has not been tested.
Relevant Links:	• UniProtKB - Q13421 • NCBI - 53988378 • GenelD - 10232

Application Details

Tested Applications:	FC, IHC, WB
Application Note:	This antibody has been tested for use in immunohistochemistry, flow cytometry, and western blotting. Specific conditions for reactivity should be optimized by the end user. Expect a band approximately 40 kDa in size corresponding to mature mesothelin by western blotting in the appropriate cell lysate or extract. For immunohistochemistry, archival PEFF human tissues were deparaffinized followed by hydration. Antigen-retrieval is recommended. Block tissues with 1% BSA in PBS for 30 min at 23° C. Antibodies are diluted in 1% BSA and reacted with tissue for 60 min at room temperature.
Assay Dilutions:	All assays should be optimized by the user. Recommended dilutions (if any) may be listed below.
ELISA:	1:10,000 - 1:50,000
IHC:	1:100
IP:	1:800
WB:	1:1,000

Formulation

Physical State:	Liquid (sterile filtered)
Concentration:	1.0 mg/mL by UV absorbance at 280 nm
Buffer:	0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2
Preservative:	0.01% (w/v) Sodium Azide
Stabilizer:	None


Shipping & Handling

Shipping Condition: Dry Ice

Storage Condition: Store vial at -20° C or below prior to opening. This vial contains a relatively low volume of reagent (25 µL). To minimize loss of volume dilute 1:10 by adding 225 µL of the buffer stated above directly to the vial. Recap, mix thoroughly and briefly centrifuge to collect the volume at the bottom of the vial. Use this intermediate dilution when calculating final dilutions as recommended below. Store the vial at -20°C or below after dilution. Avoid cycles of freezing and thawing.


Expiration: Expiration date is three (3) months from date of receipt.

Images




Flow Cytometry

Flow Cytometry Results of Anti-Mesothelin (MOUSE) Monoclonal Antibody. The green histogram shows NCI-H226 cells and blue histogram shows MCF-7 cells. Both cell lines are stained with a 1:800 dilution Anti-Mesothelin (MOUSE) Monoclonal Antibody. The secondary antibody use was Anti-Mouse IgG (H&L) (GOAT) Antibody DyLight™ 488 Conjugated (p/n 610-141-002, lot#43322) at the 1:400 dilution.



Flow Cytometry


Mesothelin expression in mesothelioma monolayers and spheroids. NCI-H226 cells incubated with an anti-mesothelin mAb (MN) and detected with goat anti-mouse IgG conjugated with Alexa488 by flow cytometry. Figure provided by CiteAb. Source: PLoS One, PMID: 21305058.



Immunohistochemistry

Mice were subcutaneously inoculated with 5×10^6 NCI-Meso29 cells and the treatment was started when tumors size reached 100 mm³. Mice were treated with no treatment; 1 cycle of 3x 2.5mg/kg RG7787 QOD i.v.; 1 cycle of 1 x 75 mg/kg nab-Paclitaxel and 1 cycle of 3 x 25mg/kg RG7787 combined with 1 cycle 1 x 75 mg/kg nab-Paclitaxel. Representative tumor tissues from different groups were harvested after the 1st cycle of the indicated treatments on Day 33, and representative H&E staining, IHC staining for MSLN and Ki-67 expression, as well as TUNEL staining with the paraffin sections of tumor tissues were shown. Scale bar in H&E, 1000 μ m. Scale bar in MSLN, Ki67, TUNEL staining, 200 μ m.

Fig 5. PMID: 27635089





Immunohistochemistry

Immunohistochemistry of Mouse anti-Mesothelin antibody. Tissue: human tonsil. Fixation: formalin fixed paraffin embedded. Antigen retrieval: not required. Primary antibody: anti-Mesothelin antibody at 15 μ g/mL for 1 h at RT. Secondary antibody: Peroxidase mouse secondary antibody at 1:10,000 for 45 min at RT. Staining: Mesothelin as precipitated red signal with hematoxylin purple nuclear counterstain.

Immunohistochemistry


Immunohistochemistry using Rockland's anti-mesothelin antibody to react with two epitopes on mesothelin in PEFF human mesothelioma tissue sections treated by antigen retrieval methods. Anti-mesothelin primary antibodies were used at 10 μ g/mL to label these sections as follows: C, MAb MB; and D, MAb MN followed by goat anti-mouse IgG conjugated to horseradish peroxidase at 25 μ g/mL in 1% BSA/PBS for 30 minutes. (magnification, $\times 200$; bar, 50 μ m). Reprinted with permission from Clin.Cancer Res. 11(16):5840-6.





Western Blot

Western Blot of Mouse Anti-Mesothelin Antibody. Lane 1: Opal Prestained Molecular Weight Marker (p/n MB-210-0500). Lane 2: HeLa [10µg] + Mesothelin-Fc [0.1µg]. Lane 3: HeLa [10µg] + Mesothelin-Fc [0.05µg]. Lane 4: HeLa [10µg] + Mesothelin-Fc [0.02µg]. Lane 5: HeLa Whole Cell Lysate (p/n W09-000-364). Primary Antibody: Anti-Mesothelin at 1µg/mL overnight at 2-8°C. Secondary Antibody: Rabbit Anti-Mouse IgG HRP conjugated (p/n 610-4302) at 1:40,000 for 30 mins at RT. Block: BlockOut Buffer (p/n MB-073) 30 mins at RT. Exposure: 15 sec. Predicted MW: 40kDa Mesothelin + Fc region 30kDa. Observed MW: ~70-75kDa.



Western Blot

Western blotting using Rockland's anti-mesothelin antibodies to detect mesothelin-Fc at 100 ng (lane 1), 25 ng (lane 2), 6 ng (lane 3), 2 ng (lane 4) and 0.4 ng (lane 5). Lane 6 contains 50 ng of CDC25-Fc. Proteins were separated on 4-20% gradient gel by SDS-PAGE followed by transfer to PVDF membrane. Primary antibody was used at 1 µg/ml followed by reaction with ALP goat anti-mouse IgG and BCIP/NBT substrate. Reprinted with permission from Clin.Cancer Res. 11(16):5840-6.

References

- Koukoulis K, et al. Targeting Mesothelin via the native T cell receptor. *BioRxiv (Preprint)* (2025)
- Liang O et al. High mesothelin expression is associated with low cytotoxic T cell infiltration in pancreatic cancer. *Front Immunol.* (2025)
- Marin-Muller C et al. Nanoparticle-Mediated Therapy with miR-198 Sensitizes Pancreatic Cancer to Gemcitabine Treatment through Downregulation of VCP-Mediated Autophagy. *Pharmaceutics.* (2023)
- Suurs FV et al. Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues. *J Nucl Med.* (2021)
- Jewell ML et al. Single-Cell RNA Sequencing Identifies Yes-Associated Protein 1–Dependent Hepatic Mesothelial Progenitors in Fibrolamellar Carcinoma. *Am J Pathol.* (2020)
- Inoue S. et al. Diffuse mesothelin expression leads to worse prognosis through enhanced cellular proliferation in colorectal cancer. *Oncology Letters* (2020)
- Oehl et al. Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression. *Frontiers in Oncology* (2018)
- Zhang et al. Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient-Derived Xenografts and Mesothelin as a Biomarker of Tumor Response. *Clinical Cancer Research* (2017)
- Leshem, Y et al. Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity. *Cancer Immunology Research* (2017)
- Illei, PB et al. Mesothelin Expression in Advanced Gastroesophageal Cancer Represents a Novel Target for Immunotherapy. *Applied Immunohistochemistry & Molecular Morphology : Aimm* (2016)
- Awuah et al. Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins. *Molecular Cancer Therapeutics* (2016)
- Khanna et al. Malignant Mesothelioma Effusions Are Infiltrated by CD3+ T Cells Highly Expressing PD-L1 and the PD-L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti-PD-L1 Antibody Avelumab. *Journal of Thoracic Oncology* (2016)
- Alewine, C et al. Efficacy of RG7787, a next-generation mesothelin-targeted immunotoxin, against triple-negative breast and gastric cancers. *Molecular Cancer Therapeutics* (2014)
- Zhang, J et al. Megakaryocytic potentiating factor and mature mesothelin stimulate the growth of a lung cancer cell line in the peritoneal cavity of mice. *PLoS One* (2014)
- Zhang, J et al. Loss of mesothelin expression by mesothelioma cells grown in vitro determines sensitivity to anti-mesothelin immunotoxin SS1P. *Anticancer Research* (2012)
- Feng, M et al. In vivo imaging of human malignant mesothelioma grown orthotopically in the peritoneal cavity of nude mice. *Journal of Cancer* (2011)
- Xiang X et al. The development and characterization of a human mesothelioma in vitro 3D model to investigate immunotoxin therapy. *PLoS One.* (2011)

Disclaimer

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.